Systematic Ambulatory ECG Monitoring Following TAVI
Key facts
- Where
- Québec, CanadaSee the site
Where in Canada
- Institut universitaire de cardiologie et de pneumologie de Québec - ULQuébec, CanadaContact: Emilie Pelletier beaumont, MScTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
- Trial code
- NCT07739316
- Record updated
- 4 November 2026
- Original description
This multicenter, prospective, randomized superiority trial will evaluate whether systematic 14-day ambulatory ECG monitoring following hospital discharge after transcatheter aortic valve implantation (TAVI) reduces the risk of sudden death, symptomatic arrhythmic events, or stroke within 1 year compared with standard post-discharge care. Patients undergoing successful TAVI without permanent pacemaker implantation and presenting with at least one ECG conduction abnormality at hospital discharge will be randomized to receive either ambulatory ECG monitoring or standard follow-up. All participants will undergo routine clinical follow-up at 30 days and 1 year after TAVI.Read full original descriptionShow less
Systematic Ambulatory ECG Monitoring Following TAVI: A Prospective Randomized Trial.
This multicenter, prospective, randomized superiority trial will evaluate whether systematic 14-day ambulatory ECG monitoring following hospital discharge after transcatheter aortic valve implantation (TAVI) reduces the risk of sudden death, symptomatic arrhythmic events, or stroke within 1 year compared with standard post-discharge care. Patients undergoing successful TAVI without permanent pacemaker implantation and presenting with at least one ECG conduction abnormality at hospital discharge will be randomized to receive either ambulatory ECG monitoring or standard follow-up. All participants will undergo routine clinical follow-up at 30 days and 1 year after TAVI.
Inclusion: Age >18 years; Successful TAVI procedure; Hospitalization discharge ≤72 hrs following the TAVI procedure; Presence of at least 1 ECG abnormality at hospital discharge (QRS ≥120 ms OR PR ≥200 ms).
Exclusion: Pacemaker implantation (pre- TAVI or during hospitalization after the procedure); TAVI valve-in-valve procedure; Any complication or logistic reason precluding hospital discharge ≤72 hrs following the TAVI procedure; Impossibility to obtain signed informed consent.